Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer, Daniil Stroyakovskiy, Helen J Gogas et al. · The Lancet · 2020
Cited by 662 works. doi:10.1016/s0140-6736(20)30934-x
Authors
- Ralf Gutzmer
- Daniil Stroyakovskiy
- Helen J Gogas
- Caroline Robert
- Karl D. Lewis
- Svetlana A. Protsenko
- Rodrigo Perez Pereira
- Thomas Eigentler
- Piotr Lukasz Rutkowski
- Лев Вадимович Демидов
- Georgy Moiseevich Manikhas
- Yibing Yan
- Kuan-Chieh Huang
- Anne R. Uyei
- Virginia A. McNally
- Grant A. McArthur
- Paolo A. Ascierto
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Counting Processes and Survival Analysis.
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma